BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bergqvist V, Kadivar M, Molin D, Angelison L, Hammarlund P, Olin M, Torp J, Grip O, Nilson S, Hertervig E, Lillienau J, Marsal J. Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease. Therap Adv Gastroenterol 2018;11:1756284818801244. [PMID: 30344642 DOI: 10.1177/1756284818801244] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Pierik MJ, van der Meulen AE, Van der Linde K, Lutgens M, Kuijvenhoven JP, Akol H, Klompmaker IJ, Sikkens MSG, van Megen YJB, Stoop CM, Bloemsaat-minekus JPJ, Dijkstra G. Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease Patients. Crohn's & Colitis 360 2022;4. [DOI: 10.1093/crocol/otab001] [Reference Citation Analysis]
2 Marsal J, Barreiro-de Acosta M, Blumenstein I, Cappello M, Bazin T, Sebastian S. Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Front Med 2022;9:897936. [DOI: 10.3389/fmed.2022.897936] [Reference Citation Analysis]
3 Hillhouse E, Mathurin K, Bibeau J, Parison D, Rahal Y, Lachaine J, Beauchemin C. The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review. Adv Ther 2022;39:455-87. [PMID: 34780028 DOI: 10.1007/s12325-021-01951-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
4 Huguet JM, Cortés X, Bosca-Watts MM, Aguas M, Maroto N, Martí L, Amorós C, Paredes JM. Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease. World J Clin Cases 2021; 9(36): 11285-11299 [DOI: 10.12998/wjcc.v9.i36.11285] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Mazza S, Piazza O Sed N, Conforti FS, Fascì A, Rimondi A, Marinoni B, Casini V, Ricci C, Munari F, Pirola L, Invernizzi P, Girelli C, Lupinacci G, Pastorelli L, Cavallaro F, Ferraris L, Colucci A, Amato A, Eugenio Tontini G, Vecchi M, Fiorino G, Caprioli F. Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study. Clin Transl Sci 2021. [PMID: 34523800 DOI: 10.1111/cts.13131] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
6 Bhat S, Limdi JK, Cross RK, Farraye FA. Does Similarity Breed Contempt? A Review of the Use of Biosimilars in Inflammatory Bowel Disease. Dig Dis Sci 2021;66:2513-32. [PMID: 34176024 DOI: 10.1007/s10620-021-07114-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Limdi JK, Farraye FA. The Great Debate With IBD Biosimilars. Crohn's & Colitis 360 2021;3. [DOI: 10.1093/crocol/otab015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Hanzel J, Jansen JM, Ter Steege RWF, Gecse KB, D'Haens GR. Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study. Inflamm Bowel Dis 2022;28:495-501. [PMID: 34013959 DOI: 10.1093/ibd/izab099] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
9 Khan N, Patel D, Pernes T, Patel M, Trivedi C, Medvedeva E, Xie D, Yang Y. The Efficacy and Safety of Switching From Originator Infliximab to Single or Double Switch Biosimilar Among a Nationwide Cohort of Inflammatory Bowel Disease Patients. Crohn's & Colitis 360 2021;3:otab022. [DOI: 10.1093/crocol/otab022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Lee SJ, Baek K, Lee S, Lee YJ, Park JE, Lee SG. Post-Marketing Pooled Safety Analysis for CT-P13 Treatment of Patients with Immune-Mediated Inflammatory Diseases in Observational Cohort Studies. BioDrugs 2020;34:513-28. [PMID: 32356239 DOI: 10.1007/s40259-020-00421-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
11 Queiroz NSF, Saad-Hossne R, FrÓes RSB, Penna FGCE, Gabriel SB, Martins AL, Teixeira FV. DISCONTINUATION RATES FOLLOWING A SWITCH FROM A REFERENCE TO A BIOSIMILAR BIOLOGIC IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. Arq Gastroenterol 2020;57:232-43. [PMID: 32935741 DOI: 10.1590/S0004-2803.202000000-45] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
12 Martín-Gutiérrez N, Sánchez-Hernández JG, Rebollo N, Pordomingo AF, Muñoz F, Otero MJ. Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease. Eur J Hosp Pharm 2020:ejhpharm-2020-002410. [PMID: 33115797 DOI: 10.1136/ejhpharm-2020-002410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Haifer C, Srinivasan A, An YK, Picardo S, van Langenberg D, Menon S, Begun J, Ghaly S, Thin L. Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study. Med J Aust 2021;214:128-33. [PMID: 33070332 DOI: 10.5694/mja2.50824] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
14 Kumari A, Prasad DN, Kumar S, Singh RK. Clinical Benefits of Switching from Original Infliximab to its Biosimilar (CT-P13) as a Potential TNF-α Inhibitor. Journal of Exploratory Research in Pharmacology 2020;000:1-9. [DOI: 10.14218/jerp.2020.00004] [Reference Citation Analysis]
15 Albshesh A, Ben-Horin S. CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel disease. Expert Opin Biol Ther 2019;19:971-8. [PMID: 31401899 DOI: 10.1080/14712598.2019.1653848] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
16 Guerra Veloz MF, Belvis Jiménez M, Valdes Delgado T, Castro Laria L, Maldonado Pérez B, Perea Amarillo R, Merino Bohórquez V, Caunedo Álvarez Á, Vilches Arenas Á, Argüelles-Arias F. Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data. Therap Adv Gastroenterol 2019;12:1756284819858052. [PMID: 31258621 DOI: 10.1177/1756284819858052] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
17 Fiorino G, Caprioli F, Daperno M, Mocciaro F, Principi M, Viscido A, Fantini MC, Orlando A, Papi C, Annese V, Danese S, Vecchi M, Rizzello F, Armuzzi A; National patients’ association representatives. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Dig Liver Dis 2019;51:632-9. [PMID: 30872085 DOI: 10.1016/j.dld.2019.02.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
18 Tursi A, Mocci G, Faggiani R, Allegretta L, Valle ND, Forti G, Franceschi M, Ferronato A, Gallina S, Larussa T, Luzza F, Lorenzetti R, Penna A, Rodino S, Sebkova L, Lauria A, Piergallini S, Pranzo G, Ricciardelli C, Zampaletta C, Elisei W, Picchio M. Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers. Ann Gastroenterol 2019;32:392-9. [PMID: 31263362 DOI: 10.20524/aog.2019.0377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
19 Milassin Á, Fábián A, Molnár T. Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective. Therap Adv Gastroenterol 2019;12:1756284819842748. [PMID: 31019554 DOI: 10.1177/1756284819842748] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
20 Papamichael K, Lin S, Moore M, Papaioannou G, Sattler L, Cheifetz AS. Infliximab in inflammatory bowel disease. Ther Adv Chronic Dis 2019;10:2040622319838443. [PMID: 30937157 DOI: 10.1177/2040622319838443] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 14.0] [Reference Citation Analysis]
21 Nielsen OH, Ainsworth MA. Biosimilars for Management of Crohn Disease. Ann Intern Med 2019;170:129. [DOI: 10.7326/m18-3060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
22 Fiorino G, Gilardi D, Correale C, Furfaro F, Roda G, Loy L, Argollo M, Allocca M, Peyrin-biroulet L, Danese S. Biosimilars of adalimumab: the upcoming challenge in IBD. Expert Opinion on Biological Therapy 2019;19:1023-30. [DOI: 10.1080/14712598.2019.1564033] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]